HPV vaccine and herpes vaccine are included in the key development of vaccine

On July 28, Wang Lixin, deputy director of the inspection center of the Jiangsu Provincial Drug Administration, led the relevant personnel of the vaccine and biological product inspection department to visit Jiangsu Ruike Biotechnology Co., Ltd. The vaccine and herpes vaccine are included in the key development of vaccine by the "Fourteenth Five -Year Plan". Essence

Wang Lixin and his party visited the Ruico Biological Reorganization Dual Elected Crown Pneumonia Vaccine (CHO Cell) ("RecoV") raw liquid production line, packaging production line, QC laboratory and other facilities. Progress and listing. During the visit, the company's leaders introduced the development of the company's development, basic situation, and technical strength. The research team highly evaluated the achievements of Ruico Bio for more than 10 years.

Subsequently, the research team conducted guidance on the EUA declaration and quality management GMP compliance of the Ruico biological RECOV vaccine, and answered the design of the factory facilities and the key craftsmanship parameters of the vaccine, the production of the antigen and the agent, the production of the vaccine, Verification and process verification issues have effectively solved the problem of urgency and eagerness of enterprises, helping enterprises to seize the requirements of regulatory guidelines and core quality management concepts.

It is worth noting that the vaccine new agent has been listed as one of the pharmaceutical industrialization technology research projects by the "Fourteenth Five -Year Plan" pharmaceutical industry development plan, and it is also an important direction for the construction of new vaccine research and development and industrialization capabilities. At the same time, the HPV vaccine and herpes vaccine were also included in the key development varieties of the vaccine.

Reporter Hualinyue

- END -